As Eli Lilly ends the year with Zepbound in good supply, TD Cowen analyst Steve Scaliaasked CEO David Ricks if the company ...

January 2025 kicked off with a wave of impactful biotech deals, setting the stage for an exciting year of innovation.

The 90 million euros ($94 million) raised by Orbis Medicines in a series A round was not January’s biggest venture investment ...

The discontinuation comes after the investigational drug, volenrelaxin, failed a related heart failure study in an ...

The FDA granted approval to Eli Lilly and Company’s mirikizumab-mrkz (Omvoh) for Crohn disease, expanding its treatment reach ...

A new study led by Western researchers found frequent treatment with intranasal oxytocin – a hormone in the brain associated ...

Eli Lilly and venture capital firm Andreessen Horowitz ... s R&D expertise to “foster a technology ecosystem of ambitious bio + health entrepreneurs and innovators,” according to a Jan ...

In an apparently unprecedented move, Eli Lilly is partnering with the fabled ... Vineeta Agarwala, a partner at Andreessen’s biotech arm, a16z Bio + Health, said the deal aims to combine ...

Vijay Pande, PhD, founding investor of Andreessen Horowitz's Bio + Health fund and a general partner with the tech venture capital firm , discusses how AI’s uptake in healthcare will shape its ...

Andreessen Horowitz noted on the 10th (local time) that it will collaborate with Eli Lilly to create the first venture capital fund aimed at promoting extensive innovation in the bio sector.

Bio + Health today announced a newly formed, first-of-its-kind venture capital fund to fuel broader innovation in human health, in partnership with Eli Lilly and Company (“Lilly”). The Biotech ...

K-Bio leaders pursue U.S. factories and conferences during Lunar New Year K-Bio executives opt for international business ...